Key Updates in the WHO Classification of Gastrointestinal Tumours, 6th Edition: A Rigorous Narrative Review

DR. JAINAB ZUBETHA.Z[1], DR. R.GOVINDARAJAN[2], DR. R.REVATHI SHREE[3], DR.P.PRIYANKA[4]

1. Final Year Postgraduate, Department of Pathology, Shri Sathya Sai Medical College & Research Institute, (Sri Balaji Vidyapeeth University (DU), Chennai campus), Ammapettai, Nellikuppam Post, Chengalpattu District, Tamilnadu, 603108, India
2. Professor & Head, Department of Pathology, Shri Sathya Sai Medical College & Research Institute, (Sri Balaji Vidyapeeth University (DU), Chennai campus), Ammapettai, Nellikuppam Post, Chengalpattu District Tamilnadu, 603108, India
3. Professor, Department of Pathology, Shri Sathya Sai Medical College & Research Institute, (Sri Balaji Vidyapeeth University (DU), Chennai campus), Ammapettai, Nellikuppam Post, Chengalpattu District Tamilnadu, 603108, India
4. Professor, Department of Pathology, Shri Sathya Sai Medical College & Research Institute, (Sri Balaji Vidyapeeth University (DU), Chennai campus), Ammapettai, Nellikuppam Post, Chengalpattu District Tamilnadu, 603108, India

Abstract

Background

The World Health Organization (WHO) Classification of Tumours serves as the global standard for the diagnosis and classification of gastrointestinal (GI) neoplasms. The recently published sixth edition of the WHO Classification of Tumours of the Digestive System incorporates significant advances in tumour biology, molecular pathology, immunohistochemistry, hereditary cancer syndromes, digital pathology, and precision oncology. These updates reflect the rapidly evolving understanding of gastrointestinal malignancies and have important implications for diagnostic accuracy, prognostic assessment, pathological reporting, and personalized patient management.

Objective

To critically review the major updates introduced in the sixth edition of the WHO Classification of Tumours of the Digestive System and discuss their diagnostic, molecular, clinical, and research implications for contemporary gastrointestinal pathology.

Data Sources

A rigorous narrative review was conducted using the WHO Classification of Tumours (4th, 5th, and 6th editions), WHO Classification Online, International Agency for Research on Cancer (IARC) publications, NCCN and ESMO clinical practice guidelines, and peer-reviewed literature indexed in PubMed and other major biomedical databases.

Content

The review summarizes the evolution of the WHO classification from earlier morphology-based systems to the current integrated histomolecular framework. Major developments include revised tumour taxonomy, updated diagnostic criteria, expanded recognition of hereditary tumour syndromes, advances in immunohistochemistry, incorporation of clinically actionable molecular biomarkers, refinement of neuroendocrine neoplasm classification, and increasing integration of artificial intelligence and digital pathology. The review also discusses the alignment of the WHO classification with international clinical practice guidelines, its contribution to precision oncology, standardized pathological reporting, multidisciplinary cancer care, epidemiological surveillance, and future directions in gastrointestinal tumour classification.

Conclusion

The sixth edition of the WHO Classification of Tumours of the Digestive System represents a major advancement in gastrointestinal pathology by integrating conventional histopathology with molecular diagnostics, immunophenotyping, and precision medicine. Its adoption is expected to improve diagnostic reproducibility, facilitate biomarker-driven therapeutic decision-making, strengthen multidisciplinary collaboration, and support international research and cancer control initiatives. Continuous incorporation of emerging technologies,

including digital pathology, artificial intelligence, and multi-omics approaches, will further enhance future editions and contribute to more precise and personalized management of gastrointestinal malignancies.

Keywords: WHO Classification of Tumours, Digestive System Tumours, Gastrointestinal Neoplasms, Histopathology, Molecular Pathology, Precision Oncology, Immunohistochemistry, Digital Pathology, Artificial Intelligence, Narrative Review.

How to cite this article: Zubetha Z J, Govindarajan R, Revathi Shree R, Priyanka P. Key Updates in the WHO Classification of Gastrointestinal Tumours, 6th Edition: A Rigorous Narrative Review. Int J Drug Deliv Technol. 2026;16(69s):1109-1124. DOI: 10.25258/ijddt.16.69s.114

Introduction

Gastrointestinal (GI) cancers constitute one of the most significant contributors to the global burden of malignancy, accounting for a considerable proportion of cancer incidence and mortality worldwide. According to the International Agency for Research on Cancer (IARC), cancers involving the colorectum, stomach, esophagus, liver, pancreas, and other digestive organs collectively account for millions of newly diagnosed cases and cancer-related deaths each year, making them a major public health concern across both developed and developing countries.[1] Despite substantial advances in screening, diagnostic modalities, molecular biology, and therapeutic interventions, the prognosis of many gastrointestinal malignancies remains poor because of delayed diagnosis, marked biological heterogeneity, and variable responses to treatment. Consequently, accurate pathological diagnosis and standardized tumour classification have become increasingly important for guiding clinical management, improving prognostic assessment, facilitating multidisciplinary communication, and ensuring comparability across clinical trials and international cancer registries.

The World Health Organization (WHO) Classification of Tumours serves as the internationally accepted reference standard for the diagnosis and classification of human neoplasms. Since the publication of the first WHO Blue Book, successive editions have continually evolved to incorporate advances in pathology, molecular biology, genetics, and clinical oncology. The publication of the **sixth edition of the WHO Classification of Tumours of the Digestive System** represents the most comprehensive revision to date, integrating recent developments in histopathology, molecular diagnostics, immunohistochemistry, hereditary cancer syndromes, and precision medicine into routine pathological practice.[2] Rather than functioning solely as a descriptive classification, the sixth edition establishes an evidence-based framework that supports standardized diagnosis, enhances reproducibility among pathologists, and aligns pathological reporting with contemporary clinical management strategies.

The sixth edition introduces several conceptual and structural modifications that distinguish it from previous classifications. These include refinement of tumour nomenclature, updated diagnostic criteria, incorporation of clinically relevant molecular biomarkers, expanded recognition of hereditary tumour syndromes, revised grading systems, improved classification of neuroendocrine neoplasms, and greater integration of digital pathology and computational advances. These changes reflect the rapid evolution of gastrointestinal oncology over the past decade and acknowledge that tumour morphology alone is often insufficient to explain biological behaviour, prognosis, or therapeutic responsiveness. Consequently, histopathological evaluation is increasingly complemented by molecular profiling and immunophenotypic characterization to achieve integrated histomolecular diagnosis.[3]

The previous **fifth edition**, published in 2019, represented an important milestone by introducing several molecular concepts into gastrointestinal tumour classification. It standardized terminology across multiple organ systems, refined diagnostic criteria for numerous epithelial and mesenchymal tumours, and strengthened the relationship between pathological diagnosis and precision oncology. However, since its publication, remarkable advances in cancer genomics, artificial intelligence, digital pathology, epigenetics, biomarker discovery, and targeted therapeutics have generated substantial new evidence that warranted further revision. The sixth edition therefore builds upon the strengths of the fifth edition while incorporating contemporary scientific discoveries that have emerged during recent years.[4]

One of the defining characteristics of the latest WHO classification is its emphasis on integrating morphology with molecular pathology. Histopathological examination remains the cornerstone of diagnosis; however, the identification of specific molecular alterations has become indispensable in characterizing tumour subtypes, determining prognosis, predicting therapeutic response, and identifying hereditary cancer syndromes. Molecular abnormalities including microsatellite instability, mismatch repair deficiency, KRAS, NRAS, BRAF, HER2

amplification, FGFR alterations, and NTRK gene fusions now influence not only therapeutic decision-making but also disease classification itself. This integrated approach reflects the growing transition toward precision oncology, where treatment strategies are increasingly tailored according to individual tumour biology rather than anatomical location alone.

The importance of standardized tumour classification extends beyond individual patient care. Uniform diagnostic terminology facilitates effective communication among pathologists, surgeons, gastroenterologists, medical oncologists, radiation oncologists, geneticists, and researchers, thereby strengthening multidisciplinary management of gastrointestinal malignancies. Standardized classifications also enhance the quality of epidemiological surveillance, cancer registration, translational research, and international collaborative studies by ensuring that diagnostic criteria remain consistent across institutions and geographical regions. Such harmonization is particularly important in an era where multicentre clinical trials and global research collaborations increasingly rely upon reproducible pathological diagnoses.

The evolving landscape of gastrointestinal oncology has also highlighted the need for continuous revision of tumour classification systems. Advances in high-throughput sequencing technologies, transcriptomics, proteomics, metabolomics, and spatial biology have substantially expanded understanding of tumour heterogeneity and carcinogenesis. These technologies have demonstrated that morphologically similar tumours may possess distinct molecular signatures associated with different biological behaviour, therapeutic sensitivity, and clinical outcomes. Recognition of these differences has transformed traditional concepts of tumour classification and supports the development of biologically meaningful diagnostic categories capable of improving patient outcomes.

To accommodate these scientific developments, the WHO has progressively adopted a multidisciplinary approach in developing successive tumour classifications. Expert pathologists, molecular biologists, oncologists, surgeons, geneticists, epidemiologists, and other specialists collectively contribute to evidence synthesis and consensus recommendations. This collaborative process ensures that the WHO Classification reflects both contemporary scientific evidence and practical applicability across healthcare systems with varying levels of diagnostic resources. The sixth edition therefore balances the incorporation of sophisticated molecular diagnostics with the continued importance of conventional histopathology, ensuring global applicability while encouraging progressive implementation of precision medicine.

The present review has been prepared as a **rigorous narrative review**, following the principles described by Sukhera, which emphasize transparency, clearly defined objectives, comprehensive evidence synthesis, and critical interpretation rather than simple descriptive summarization.[5] Narrative reviews are particularly appropriate when addressing evolving classification systems and multidisciplinary concepts where evidence originates from consensus documents, practice guidelines, original investigations, and expert reviews. Rather than attempting exhaustive systematic synthesis, this review critically integrates current evidence to provide a comprehensive overview of the major conceptual and diagnostic advances introduced in the sixth edition of the WHO Classification of Tumours of the Digestive System.

The clinical significance of the updated WHO classification extends directly to contemporary management guidelines. Current recommendations from the National Comprehensive Cancer Network (NCCN) emphasize that pathological diagnosis should incorporate both morphological assessment and clinically relevant molecular biomarkers for colorectal malignancies, enabling individualized therapeutic strategies and accurate prognostic stratification.[6] Similar recommendations have been incorporated into guidance for rectal cancer, where standardized pathological reporting and biomarker evaluation play central roles in treatment planning, neoadjuvant therapy selection, and postoperative management.[7]

Scientific Advances Driving the WHO 6th Edition of the Classification of Digestive System Tumours

Integration of Contemporary Clinical Practice into the WHO Classification

The sixth edition of the WHO Classification of Tumours of the Digestive System extends beyond a purely pathological framework by aligning diagnostic criteria with contemporary evidence-based clinical practice. Advances in gastrointestinal oncology have increasingly demonstrated that pathological diagnosis should not be considered an isolated discipline but rather an integral component of multidisciplinary cancer care. Modern management algorithms require pathologists to provide detailed histopathological, immunophenotypic, and molecular information that directly influences therapeutic decision-making. Consequently, the WHO classification has evolved to incorporate clinically actionable biomarkers and standardized reporting practices that support precision medicine.

The latest recommendations from the National Comprehensive Cancer Network (NCCN) emphasize the importance of comprehensive pathological assessment in gastric cancer, including accurate tumour typing, grading, assessment of resection margins, lymphovascular invasion, and molecular biomarker evaluation whenever clinically indicated. Biomarkers such as HER2 expression, mismatch repair (MMR) status, microsatellite instability (MSI), programmed death-ligand 1 (PD-L1), and Epstein–Barr virus (EBV) status have become increasingly relevant because they influence eligibility for targeted therapy and immunotherapy. The WHO sixth edition mirrors these developments by integrating molecular characteristics into tumour classification while maintaining morphology as the diagnostic foundation.[8]

Similar developments have occurred in the management of oesophageal and oesophagogastric junction malignancies. Current NCCN recommendations advocate standardized pathological classification, accurate assessment of tumour subtype, evaluation of treatment response following neoadjuvant therapy, and incorporation of molecular biomarkers into clinical decision-making. These recommendations highlight the growing importance of harmonizing pathological diagnosis with therapeutic strategies, particularly in the era of multimodal treatment involving surgery, chemotherapy, radiotherapy, and immunotherapy. The WHO classification provides the standardized pathological language required for such multidisciplinary management.[9]

The European Society for Medical Oncology (ESMO) likewise emphasizes the central role of pathology in gastric cancer management. Accurate histological classification, appropriate specimen handling, molecular characterization, and standardized reporting have become essential prerequisites for individualized treatment planning. The integration of internationally accepted pathological criteria into therapeutic guidelines demonstrates the close relationship between tumour classification and patient management, reinforcing the importance of periodic revision of the WHO classification to reflect evolving scientific evidence.[10]

Similarly, contemporary ESMO recommendations for colorectal cancer recognize pathology as the cornerstone of diagnosis and prognostication. Beyond conventional histological examination, pathological evaluation now routinely incorporates assessment of molecular alterations that influence therapeutic selection, familial cancer risk assessment, and prediction of treatment response. These developments have reinforced the transition from purely morphology-based diagnosis toward integrated histomolecular classification, a principle that underpins the sixth edition of the WHO Blue Book.[11]

Epigenetic Alterations and Their Role in Gastrointestinal Tumour Classification

Among the major scientific developments influencing the latest WHO classification is the growing understanding of epigenetic mechanisms involved in gastrointestinal carcinogenesis. Unlike genetic mutations that alter DNA sequence, epigenetic modifications regulate gene expression through reversible mechanisms including DNA methylation, histone modification, chromatin remodeling, and non-coding RNA regulation. These processes play fundamental roles in tumour initiation, progression, invasion, metastasis, and therapeutic resistance across multiple gastrointestinal malignancies.[12]

In colorectal carcinoma, aberrant DNA methylation contributes to silencing of tumour suppressor genes and is closely associated with the CpG island methylator phenotype (CIMP), an important molecular subtype characterized by widespread promoter hypermethylation. Likewise, defective DNA mismatch repair frequently arises through epigenetic silencing of MLH1, resulting in microsatellite instability and increased responsiveness to immune checkpoint inhibitors. Similar epigenetic alterations have been identified in gastric, oesophageal, pancreatic, and hepatobiliary malignancies, further highlighting their diagnostic and therapeutic significance.[12]

Recognition of these molecular mechanisms has substantially influenced contemporary tumour classification. Rather than relying exclusively on microscopic morphology, the WHO sixth edition acknowledges that epigenetic alterations contribute to biologically distinct tumour subgroups with differing prognostic and therapeutic implications. Consequently, molecular pathology is increasingly incorporated into routine diagnostic practice, complementing conventional histopathological assessment and facilitating precision oncology.

Expanding Role of Immunohistochemistry in Modern Gastrointestinal Pathology

Immunohistochemistry (IHC) has become an indispensable component of gastrointestinal pathology by improving diagnostic accuracy, reducing interobserver variability, and supporting molecular interpretation. Although morphological examination remains the cornerstone of diagnosis, immunohistochemical markers provide valuable information regarding tumour differentiation, cellular lineage, primary site identification,

prognostic stratification, and prediction of therapeutic response.[13]

Several immunohistochemical markers now play central roles in routine diagnostic practice. SATB2 and CDX2 assist in confirming colorectal differentiation, while CK7 and CK20 facilitate distinction between primary and metastatic adenocarcinomas. Neuroendocrine tumours routinely employ synaptophysin, chromogranin A, and INSM1 to establish neuroendocrine differentiation. Gastrointestinal stromal tumours are characterized using KIT (CD117), DOG1, and SDHB immunostaining, whereas mismatch repair protein immunohistochemistry provides a practical surrogate for microsatellite instability testing and facilitates identification of hereditary cancer syndromes such as Lynch syndrome.[13]

The WHO sixth edition emphasizes integrated interpretation of morphology, immunophenotype, and molecular alterations rather than reliance on individual biomarkers alone. Such multidimensional assessment improves diagnostic reproducibility and enables more accurate clinicopathological correlation.

Artificial Intelligence and Digital Pathology

Rapid advances in artificial intelligence (AI) and computational pathology have introduced new opportunities for improving diagnostic accuracy and workflow efficiency. Deep-learning algorithms trained on large digital pathology datasets can identify complex histological patterns, quantify tumour architecture, predict molecular alterations, estimate prognosis, and assist in tumour grading with remarkable accuracy.[14]

Foundation models trained using millions of digitized histopathological images represent an important milestone in computational pathology. These models are capable of extracting highly complex morphological features that correlate with molecular alterations and clinical outcomes while providing decision-support tools for practicing pathologists. Although AI is unlikely to replace expert pathological interpretation, it is expected to function as an adjunctive technology that enhances diagnostic consistency, reduces observer variability, and improves laboratory efficiency.[14]

The WHO sixth edition recognizes digital pathology as an emerging component of modern diagnostic practice and anticipates increasing incorporation of computational pathology into future classifications as evidence continues to accumulate.

Standardization of Pathology Reporting

Standardized pathology reporting has become increasingly important for ensuring diagnostic reproducibility, improving communication among multidisciplinary teams, and facilitating international research collaboration. Variability in pathological terminology and reporting practices has historically contributed to inconsistencies in clinical management and limited comparability between institutions. To address these challenges, international organizations have promoted structured reporting systems based upon standardized diagnostic criteria.[15]

The WHO Classification of Tumours Living Evidence Gap Map represents an important innovation that supports continual evaluation of emerging scientific evidence and identifies areas requiring further investigation. Rather than relying solely upon periodic revisions, this framework promotes continuous evidence synthesis, allowing future classifications to evolve more efficiently while maintaining scientific rigor. Standardized reporting also facilitates integration of pathology data into clinical trials, cancer registries, translational research, and quality assurance programmes.[15]

Future Research Priorities in Gastrointestinal Oncology

Continued progress in gastrointestinal oncology depends upon coordinated international research efforts that integrate molecular biology, pathology, genomics, epidemiology, artificial intelligence, and clinical medicine. The European Groundshot initiative highlights the importance of collaborative research aimed at improving early diagnosis, biomarker discovery, precision therapeutics, implementation science, and equitable access to innovative cancer care across healthcare systems.[16]

Future editions of the WHO Classification of Tumours are expected to incorporate advances in multi-omics technologies, spatial transcriptomics, digital pathology, liquid biopsy, and artificial intelligence. These emerging technologies will further refine tumour classification by identifying biologically meaningful disease subgroups and clinically actionable molecular signatures. At the same time, maintaining global applicability will remain essential so that standardized diagnostic criteria continue to benefit both resource-rich and resource-limited healthcare settings.[16]

Collectively, these scientific advances have transformed gastrointestinal pathology from a discipline centred primarily on microscopic morphology into an integrated science combining histopathology, molecular diagnostics,

computational pathology, and precision medicine. The WHO sixth edition represents the current culmination of this evolution and provides a robust foundation for future innovations in gastrointestinal cancer diagnosis and management.

Evolution of the WHO Classification and Emerging Concepts in Gastrointestinal Tumour Pathology

Evolution from the Fourth to the Sixth WHO Classification

The classification of gastrointestinal tumours has undergone a remarkable transformation over the past two decades, reflecting rapid advances in pathology, molecular biology, genetics, and clinical oncology. The publication of the **2019 WHO Classification of Tumours of the Digestive System** represented a significant milestone by introducing a more integrated diagnostic approach that combined conventional histomorphology with immunohistochemistry and molecular pathology. Compared with earlier editions, the fifth edition refined tumour terminology, updated diagnostic criteria for numerous epithelial and non-epithelial neoplasms, recognized several newly described tumour entities, and incorporated clinically relevant molecular biomarkers into routine pathological practice. These changes established the foundation upon which the sixth edition has subsequently expanded, providing a more comprehensive and biologically relevant framework for gastrointestinal tumour classification.[17]

The evolution from the fifth to the sixth edition has been driven by substantial improvements in understanding tumour biology. Increasing evidence has demonstrated that tumours sharing similar microscopic morphology frequently possess distinct molecular signatures, resulting in marked differences in biological behaviour, prognosis, and therapeutic response. Consequently, the sixth edition moves beyond purely descriptive pathology by integrating histological findings with molecular alterations whenever sufficient evidence supports their diagnostic or clinical significance. This transition represents a paradigm shift toward integrated histomolecular diagnosis and reflects the broader movement toward precision oncology.

Recognition of Genetic Tumour Syndromes

An important conceptual advance incorporated into the latest WHO framework is the expanded recognition of hereditary tumour syndromes. Hereditary gastrointestinal cancers account for a relatively small proportion of all digestive tract malignancies; however, their identification has profound implications for patient management, family screening, surveillance, and preventive strategies. The WHO now emphasizes the importance of recognizing inherited cancer predisposition syndromes as part of routine pathological evaluation rather than considering them solely within the domain of clinical genetics.[18]

Pathologists play a central role in identifying morphological features suggestive of inherited cancer syndromes. Histopathological findings, when interpreted together with immunohistochemistry and molecular testing, may provide the first indication of syndromes such as Lynch syndrome, familial adenomatous polyposis, Peutz–Jeghers syndrome, juvenile polyposis syndrome, MUTYH-associated polyposis, and hereditary diffuse gastric cancer. Early recognition of these entities enables appropriate genetic counselling, cascade testing of family members, implementation of surveillance programmes, and risk-reducing interventions. Consequently, hereditary tumour syndromes have become an integral component of modern gastrointestinal pathology and are increasingly embedded within the WHO classification framework.[18]

Public Health Impact of Standardized Tumour Classification

The significance of the WHO Classification extends well beyond individual diagnostic practice. Standardized tumour classification provides the foundation for reliable epidemiological surveillance, cancer registration, health policy development, clinical research, and international collaboration. Uniform terminology ensures that pathological diagnoses remain comparable across institutions and countries, facilitating multicentre studies and improving the quality of population-based cancer data.[19]

The impact of standardized classification is particularly evident in cancer registries, where consistent diagnostic criteria enable accurate estimation of disease incidence, survival, mortality, and temporal trends. These data inform national cancer control programmes, resource allocation, screening strategies, and health economic evaluations. Furthermore, standardized pathological terminology improves the quality of clinical trials by ensuring uniform eligibility criteria and reproducible outcome assessment. The WHO classification therefore contributes not only to diagnostic pathology but also to broader public health initiatives aimed at reducing the global burden of gastrointestinal malignancies.[19]

Historical Perspective: Contributions of the Fourth Edition

Although contemporary classifications increasingly incorporate molecular pathology, the foundations of current diagnostic practice remain rooted in earlier WHO editions. The fourth edition, published in

2010, represented a landmark achievement by establishing internationally standardized diagnostic criteria for digestive system tumours and providing detailed morphological descriptions for a wide spectrum of neoplastic lesions.[20]

The fourth edition significantly improved consistency in tumour nomenclature, histological grading, and diagnostic reporting while strengthening clinicopathological correlations. Many concepts introduced during this period—including standardized definitions of precursor lesions, improved subclassification of adenocarcinomas, and recognition of distinct mesenchymal tumours—continue to underpin current practice. The subsequent fifth and sixth editions have therefore evolved through refinement rather than replacement of these fundamental pathological principles.[20]

Emerging Concepts in Upper Gastrointestinal Pathology

Upper gastrointestinal pathology has undergone substantial refinement in the sixth edition owing to improved understanding of oesophageal and gastric carcinogenesis. Recent evidence has clarified the biological significance of precursor lesions, dysplastic changes, inflammatory conditions, and molecular pathways involved in tumour development, resulting in updated diagnostic criteria for several upper gastrointestinal neoplasms.[21]

Greater emphasis has been placed on accurate distinction between reactive epithelial atypia and true dysplasia, particularly in Barrett-associated lesions and chronic inflammatory disorders. Recognition of oesophageal epidermoid metaplasia as a clinically significant precursor lesion, refinement of dysplasia grading systems, and improved characterization of gastric epithelial neoplasia have enhanced diagnostic reproducibility. These developments reduce interobserver variation and strengthen pathological assessment of premalignant conditions.[21]

Advances in molecular pathology have similarly refined the classification of gastric adenocarcinoma. Contemporary diagnostic approaches increasingly integrate morphological evaluation with molecular biomarkers, including mismatch repair status, Epstein–Barr virus-associated carcinomas, and other biologically relevant tumour subgroups. Such integration provides more accurate prognostic information while supporting individualized therapeutic strategies.

Evolution of Neuroendocrine Neoplasm Classification

Neuroendocrine neoplasms represent one of the most rapidly evolving areas within gastrointestinal pathology. Historically regarded as a relatively homogeneous group, these tumours are now recognized to encompass biologically diverse entities differing in differentiation, proliferative activity, molecular alterations, prognosis, and treatment response.[22]

The WHO classification has progressively refined diagnostic criteria for neuroendocrine tumours and neuroendocrine carcinomas by incorporating objective grading systems based upon mitotic activity and Ki-67 proliferation index. Recognition of mixed neuroendocrine–non-neuroendocrine neoplasms, improved subclassification of well-differentiated neuroendocrine tumours, and clearer separation from poorly differentiated carcinomas have substantially improved diagnostic precision. These developments have facilitated more accurate prognostic stratification and individualized management.[22]

Subsequent international consensus has continued to strengthen these concepts by harmonizing neuroendocrine tumour terminology across organ systems and emphasizing the biological basis of classification. This unified approach has improved consistency among pathologists and enhanced multidisciplinary communication, thereby supporting both clinical practice and research in neuroendocrine oncology.[27]

Digital Evolution of the WHO Classification

Another important innovation accompanying the sixth edition is the continued expansion of the WHO Classification of Tumours Online platform. Unlike previous editions that relied primarily upon printed reference volumes, the digital platform enables continuous updating of diagnostic criteria as new scientific evidence emerges. This dynamic model facilitates rapid dissemination of revised terminology, molecular discoveries, and newly recognized tumour entities while maintaining international standardization.[23]

The online platform also provides improved accessibility for pathologists, clinicians, educators, and researchers worldwide. Continuous evidence integration ensures that future updates can be incorporated more efficiently than traditional edition-based revisions, allowing the WHO classification to remain responsive to ongoing advances in cancer biology and diagnostic pathology.[23]

Practical Utility of Contemporary Gastrointestinal Pathology

The increasing complexity of gastrointestinal tumour diagnosis has reinforced the importance of integrating pathology into routine clinical decision-making. Modern pathological reports are expected

to include not only tumour type and grade but also essential prognostic variables, margin status, lymphovascular invasion, biomarker results, and relevant molecular findings. Such comprehensive reporting supports multidisciplinary treatment planning and facilitates precision oncology.[24]

Pathology data also play an important role in quality assurance, audit, education, and translational research. Standardized pathological reporting improves communication among healthcare professionals while enhancing reproducibility across institutions. As molecular diagnostics become increasingly incorporated into routine practice, the role of the gastrointestinal pathologist continues to expand beyond conventional microscopy toward integrated diagnostic interpretation that combines morphology, immunophenotype, and molecular information.[25]

Collectively, these developments demonstrate that the WHO sixth edition represents the culmination of decades of scientific progress. By integrating morphology, molecular pathology, hereditary syndromes, digital technologies, and standardized reporting into a unified diagnostic framework, the current classification provides a robust foundation for precision medicine while remaining adaptable to future advances in gastrointestinal oncology.[26

Future Directions and Emerging Perspectives in the WHO Classification of Digestive System Tumours

Artificial Intelligence and Computational Pathology

The rapid advancement of artificial intelligence (AI) has introduced a transformative era in diagnostic pathology. Traditionally, histopathological diagnosis has depended on meticulous microscopic examination by experienced pathologists. Although this remains the gold standard, increasing case volumes, expanding molecular requirements, and growing diagnostic complexity have created a need for computational tools that improve efficiency while maintaining diagnostic accuracy. AI-based image analysis, particularly machine learning and deep learning algorithms, has demonstrated remarkable capability in identifying subtle morphological patterns that may not be readily appreciated through conventional microscopy.[28]

Deep learning models trained using whole-slide images have shown considerable promise in tumour detection, grading, segmentation, and quantification of histological features across a broad spectrum of gastrointestinal malignancies. Computational pathology has also demonstrated potential in predicting molecular alterations directly from routine hematoxylin and eosin-stained slides, thereby complementing conventional molecular testing. Applications include prediction of microsatellite instability, mismatch repair deficiency, tumour mutation burden, and other clinically relevant biomarkers that increasingly influence therapeutic decision-making. Such advances have the potential to reduce diagnostic turnaround time while improving reproducibility and standardization among pathology laboratories.[28]

The WHO recognizes that artificial intelligence should function as a complementary decision-support tool rather than a replacement for expert pathological interpretation. Human expertise remains essential for integrating clinical information, morphological assessment, ancillary investigations, and multidisciplinary communication. Nevertheless, computational pathology is expected to become progressively integrated into routine diagnostic workflows, particularly in high-volume centres where digital pathology infrastructure has been established.

Digital Transformation through the WHO Classification of Tumours Online

An important innovation accompanying the sixth edition is the expansion of the WHO Classification of Tumours Online platform, representing a transition from static printed reference volumes toward a continuously evolving digital resource. Unlike previous editions that required publication of entirely new books to incorporate emerging evidence, the online platform enables periodic updates reflecting newly recognized tumour entities, revised diagnostic criteria, molecular discoveries, and changes in nomenclature.[29]

This dynamic model provides several important advantages. Pathologists worldwide can access updated classifications without waiting for future editions, ensuring greater consistency in diagnostic practice. The online platform also facilitates rapid dissemination of evidence-based recommendations while supporting education, research, and international collaboration. As gastrointestinal oncology continues to evolve rapidly, the availability of continuously updated classification systems will become increasingly important for maintaining diagnostic accuracy and scientific relevance.[29]

Foundation Models and the Next Generation of Digital Pathology

Recent developments in foundation models represent another major milestone in computational pathology. Unlike conventional machine-learning systems designed for specific diagnostic tasks, foundation models are trained using extremely large collections of histopathological images, enabling them to learn generalized morphological

representations applicable across multiple tumour types and diagnostic scenarios.[30]

These models demonstrate impressive performance in tumour detection, classification, grading, prognostic prediction, and identification of clinically significant molecular alterations. By integrating information from millions of digital pathology images, foundation models provide highly adaptable computational frameworks capable of supporting routine diagnostic practice, pathology education, and translational research. Their potential applications extend beyond image interpretation to include quality assurance, workflow optimization, and identification of previously unrecognized morphological biomarkers.[30]

Although widespread clinical implementation will require further validation, regulatory oversight, and standardized quality control, foundation models are expected to play an increasingly important role in future editions of the WHO Classification by facilitating objective and reproducible pathological assessment.

Research Priorities for the Future of Gastrointestinal Oncology

Continued refinement of gastrointestinal tumour classification depends upon sustained international collaboration among pathologists, clinicians, molecular scientists, bioinformaticians, epidemiologists, and healthcare policymakers. The European Groundshot initiative has highlighted several strategic priorities, including earlier cancer detection, improved biomarker discovery, equitable implementation of precision medicine, integration of multi-omics technologies, enhanced translational research, and strengthened collaboration between research institutions across Europe and globally.[31]

These priorities extend beyond technological innovation and emphasize the need to reduce disparities in cancer care, improve access to advanced diagnostics, strengthen cancer prevention programmes, and facilitate rapid translation of scientific discoveries into clinical practice. Such coordinated research efforts are likely to influence future revisions of tumour classification while promoting more individualized approaches to gastrointestinal cancer management.[31]

Epigenetics and the Expanding Molecular Landscape

One of the most important developments influencing modern gastrointestinal pathology is the growing understanding of epigenetic regulation. Epigenetic alterations, including DNA methylation, histone modification, chromatin remodeling, and non-coding RNA regulation, influence gene expression without altering the underlying DNA sequence. These mechanisms contribute substantially to tumour initiation, progression, metastasis, and therapeutic resistance across multiple gastrointestinal malignancies.[32]

Recognition of epigenetic alterations has improved understanding of tumour heterogeneity and has identified novel biomarkers with diagnostic, prognostic, and therapeutic relevance. In colorectal carcinoma, for example, CpG island methylator phenotype and epigenetic silencing of mismatch repair genes contribute to biologically distinct tumour subgroups. Similar mechanisms have been identified in gastric, pancreatic, hepatobiliary, and oesophageal cancers, emphasizing the increasingly important role of molecular pathology within the WHO classification framework.[32]

Immunohistochemistry as an Integral Diagnostic Tool

Despite rapid advances in molecular diagnostics, immunohistochemistry remains indispensable in routine gastrointestinal pathology. Immunohistochemical markers provide valuable information regarding tumour differentiation, tissue lineage, metastatic origin, prognostic stratification, and prediction of therapeutic response. The combined interpretation of morphology and immunophenotype has become a defining feature of integrated histomolecular diagnosis.[33]

Markers such as CDX2, SATB2, CK7, CK20, DOG1, KIT, chromogranin A, synaptophysin, INSM1, and mismatch repair proteins are now routinely incorporated into diagnostic algorithms. Their standardized use has substantially improved diagnostic reproducibility while reducing interobserver variability among pathologists. The WHO sixth edition reinforces this multidimensional diagnostic approach by emphasizing integration of histopathology, immunohistochemistry, and molecular testing whenever clinically appropriate.[33]

Standardization of Pathology Reporting

Standardized pathological reporting has become essential for ensuring consistency in diagnosis, clinical communication, research, and quality assurance. Structured reporting minimizes variability, facilitates multidisciplinary decision-making, and improves the quality of cancer registry data and clinical trials. The WHO Classification of Tumours Living Evidence Gap Map represents an important initiative designed to identify knowledge gaps while continuously integrating emerging scientific evidence into future classification updates.[34]

This evidence-based approach supports ongoing refinement of diagnostic criteria, promotes

international harmonization, and ensures that future revisions remain responsive to rapidly evolving scientific knowledge.

Genetic Tumour Syndromes and Precision Prevention

Recognition of hereditary tumour syndromes has expanded considerably in recent years. Contemporary pathological evaluation increasingly incorporates morphological features suggestive of inherited cancer predisposition, facilitating timely referral for genetic counselling and molecular confirmation. Early identification of syndromes such as Lynch syndrome, familial adenomatous polyposis, hereditary diffuse gastric cancer, and Peutz–Jeghers syndrome allows implementation of surveillance programmes, preventive interventions, and family screening strategies.[35]

The WHO classification acknowledges that hereditary cancer syndromes should be considered an integral component of gastrointestinal pathology because accurate diagnosis extends beyond individual patient care to include prevention among at-risk relatives.

Broader Impact of WHO Classification

The influence of the WHO Classification extends well beyond diagnostic pathology. Standardized tumour classification improves epidemiological surveillance, facilitates multicentre research, strengthens cancer registration, supports health economic analyses, and informs public health policy. Consistent terminology enhances international collaboration while ensuring comparability of clinical outcomes across different healthcare systems.[36]

The evolution from the fourth and fifth WHO editions to the current sixth edition illustrates the continuous integration of scientific advances into practical diagnostic pathology. Earlier editions established the morphological framework for tumour classification, whereas subsequent revisions progressively incorporated molecular pathology, immunohistochemistry, precision oncology, and digital technologies.[37,38]

Overall, the sixth edition represents a significant milestone in gastrointestinal pathology by integrating conventional morphology with contemporary molecular science, computational pathology, standardized reporting, and multidisciplinary clinical care. Future revisions are expected to build upon this foundation through incorporation of artificial intelligence, multi-omics technologies, spatial biology, and continuously updated digital resources, ensuring that tumour classification remains aligned with the rapidly evolving landscape of precision oncology.

Clinical Implications, Future Perspectives, and Conclusion

Public Health and Global Impact of the WHO Classification

The influence of the WHO Classification of Tumours extends well beyond diagnostic pathology. Although primarily developed to standardize tumour diagnosis, its broader impact encompasses cancer prevention, epidemiological surveillance, healthcare planning, clinical research, education, and health economics. Uniform classification systems facilitate reliable cancer registration, improve comparability of international datasets, and enable meaningful interpretation of disease incidence, survival, and mortality trends across different populations. Such standardization is fundamental to evidence-based cancer control strategies and allows healthcare policymakers to allocate resources more efficiently while monitoring the effectiveness of national cancer programmes.[36]

The sixth edition further strengthens these objectives by incorporating contemporary molecular knowledge into routine pathological practice. Standardized diagnostic terminology improves communication between pathologists, clinicians, researchers, and public health authorities, thereby supporting multidisciplinary patient care and collaborative international research. Furthermore, harmonized classifications reduce diagnostic variability between institutions, ensuring greater consistency in clinical trials and translational research. As precision oncology becomes increasingly integrated into routine healthcare, standardized tumour classification will remain essential for equitable implementation of advanced diagnostic and therapeutic technologies.[36]

Building on Earlier WHO Classifications

The sixth edition represents the culmination of decades of scientific progress rather than an entirely new classification system. The fifth edition of the WHO Classification of Digestive System Tumours introduced several important advances, including refined tumour taxonomy, improved diagnostic definitions, incorporation of selected molecular biomarkers, and updated classification of neuroendocrine neoplasms. These revisions significantly improved diagnostic reproducibility and established the conceptual foundation for subsequent developments incorporated into the latest edition.[37]

The fourth edition remains historically important because it introduced internationally accepted diagnostic criteria that standardized gastrointestinal pathology worldwide. It provided comprehensive morphological descriptions, clarified tumour

nomenclature, and established reproducible grading systems that continue to underpin contemporary diagnostic practice. Many principles introduced in the fourth edition—including careful histopathological assessment, standardized reporting, and clinicopathological correlation—remain fundamental despite subsequent incorporation of molecular pathology and precision medicine.[38]

The transition from the fourth to the sixth edition illustrates the progressive evolution of tumour classification from morphology-based diagnosis toward integrated histomolecular characterization. Rather than replacing traditional pathology, recent editions have expanded diagnostic frameworks by incorporating molecular alterations, immunophenotypic features, hereditary tumour syndromes, and clinically actionable biomarkers into routine practice.

Clinical Translation into Evidence-Based Oncology

The clinical value of the WHO classification is reflected in its close alignment with contemporary international treatment guidelines. Current NCCN recommendations for colon cancer emphasize comprehensive pathological evaluation, including tumour subtype, grade, resection margin assessment, lymphovascular invasion, lymph node status, and evaluation of molecular biomarkers such as mismatch repair deficiency, microsatellite instability, KRAS, NRAS, and BRAF mutations where clinically indicated. Accurate pathological classification directly influences prognostic assessment, adjuvant treatment decisions, and selection of targeted therapies, highlighting the essential role of standardized pathological reporting in multidisciplinary cancer care.[39]

Similarly, NCCN guidance for gastric cancer incorporates detailed pathological characterization as an essential component of therapeutic planning. Histological subtype, tumour stage, HER2 status, mismatch repair deficiency, Epstein–Barr virus-associated carcinoma, and other biomarkers increasingly influence treatment selection, particularly with the growing availability of targeted therapies and immune checkpoint inhibitors. Integration of these biomarkers within the WHO classification supports precision medicine while maintaining internationally standardized diagnostic criteria.[40]

Pathological evaluation is equally critical in oesophageal and oesophagogastric junction malignancies. Contemporary NCCN recommendations emphasize accurate tumour classification, assessment of treatment response following neoadjuvant therapy, evaluation of resection margins, and incorporation of clinically relevant molecular findings into routine reporting. These recommendations reflect the growing importance of coordinated multidisciplinary management involving pathologists, surgeons, gastroenterologists, medical oncologists, and radiation oncologists.[41]

European Society for Medical Oncology (ESMO) guidelines similarly recognize pathology as the cornerstone of colorectal cancer diagnosis and management. Standardized histopathological reporting, combined with molecular characterization, facilitates individualized therapeutic decision-making, improves prognostic stratification, and ensures appropriate selection of patients for targeted therapy and immunotherapy. The close alignment between WHO classification criteria and international clinical guidelines illustrates the practical significance of maintaining an evidence-based and globally harmonized tumour classification system.[42]

Expanding Scope Beyond Conventional Gastrointestinal Pathology

An important conceptual feature of recent WHO classifications is the recognition that tumour classification should be coordinated across organ systems rather than developed in isolation. The WHO Classification of Haematolymphoid Tumours provides an example of this integrated approach by harmonizing terminology, molecular classification, and diagnostic criteria for lymphoid neoplasms that may involve the gastrointestinal tract. Such coordination improves consistency among WHO Blue Books and facilitates accurate diagnosis of extranodal lymphomas and other haematolymphoid disorders presenting within the digestive system.[43]

This cross-disciplinary integration highlights the increasingly interconnected nature of modern pathology. Molecular pathways, genetic alterations, and immunophenotypic profiles frequently transcend anatomical boundaries, necessitating collaboration among subspecialty pathologists and promoting a unified diagnostic framework across different tumour classifications.

Future Perspectives

The future of gastrointestinal tumour classification will likely be shaped by continued advances in genomics, transcriptomics, proteomics, metabolomics, spatial biology, artificial intelligence, and digital pathology. Integration of multi-omics technologies is expected to identify biologically meaningful tumour subgroups that cannot be recognized through morphology alone. Similarly, computational pathology and machine learning may enhance diagnostic reproducibility by identifying

subtle morphological patterns associated with clinically relevant molecular alterations.

Liquid biopsy technologies, circulating tumour DNA analysis, and advanced biomarker discovery are also expected to complement conventional tissue-based pathology, enabling earlier diagnosis, improved monitoring of treatment response, and detection of minimal residual disease. Future WHO classifications will likely incorporate these innovations while maintaining the essential role of histopathological evaluation as the foundation of tumour diagnosis.

An equally important challenge will be ensuring equitable implementation of these advances across healthcare systems with varying levels of resources. The WHO has consistently emphasized that tumour classifications should remain globally applicable while encouraging progressive adoption of emerging diagnostic technologies. Balancing scientific innovation with practical applicability will therefore remain a central objective of future editions.

Conclusion

The sixth edition of the WHO Classification of Tumours of the Digestive System represents a major advancement in gastrointestinal pathology by integrating conventional morphology with molecular pathology, immunohistochemistry, hereditary tumour syndromes, digital pathology, and precision oncology. Building upon the foundations established by earlier editions, it provides a biologically relevant and clinically applicable framework that enhances diagnostic accuracy, improves prognostic assessment, and supports individualized patient management.

Its close alignment with contemporary NCCN and ESMO guidelines demonstrates the increasing integration of pathology into multidisciplinary cancer care. Furthermore, standardized classification strengthens epidemiological surveillance, facilitates translational research, supports international collaboration, and informs public health policy. As emerging technologies continue to transform oncology, the WHO classification will remain an evolving reference that bridges scientific discovery with clinical practice. Continuous refinement through evidence-based updates will ensure that future editions continue to improve diagnostic precision and contribute to better outcomes for patients with gastrointestinal malignancies worldwide.

Table 1. Evolution and Key Advances in the WHO Classification of Digestive System Tumours

WHO Edition	Year	Major Advances	Impact on Clinical Practice	Key References
4th Edition	2010	Established standardized histopathological terminology, refined tumour nomenclature, introduced uniform grading systems, improved classification of epithelial and mesenchymal tumours	Improved diagnostic consistency and international standardization of gastrointestinal tumour reporting	38
5th Edition	2019	Incorporated molecular pathology into routine classification, revised tumour taxonomy, updated neuroendocrine neoplasm classification, recognized new tumour entities and precursor lesions	Enhanced diagnostic precision, improved clinicopathological correlation, and facilitated molecular-guided diagnosis	37

6th Edition	2025	Integrated histomolecular classification, expanded recognition of hereditary tumour syndromes, incorporated clinically actionable biomarkers, emphasized precision oncology, digital pathology, and standardized reporting	Improved personalized diagnosis, biomarker-driven therapeutic decision-making, multidisciplinary communication, and precision medicine	1,2
WHO Classification Online	2025 onwards	Dynamic online platform allowing continuous evidence updates, revised nomenclature, new tumour entities, and molecular discoveries	Enables rapid dissemination of updated diagnostic criteria and global accessibility	23,29

Table 2. Major Scientific Advances Incorporated into the WHO 6th Edition

Scientific Domain	Key Advances	Clinical Significance	Reference(s)
Histopathology	Refined tumour terminology, grading systems, and diagnostic criteria	Improved diagnostic reproducibility	2,37
Molecular Pathology	Integration of MSI, MMR, HER2, KRAS, NRAS, BRAF, FGFR, NTRK biomarkers	Supports precision oncology and targeted therapy	12
Immunohistochemistry	Increased use of SATB2, CDX2, DOG1, KIT, SDHB, INSM1, Synaptophysin, Chromogranin	Enhanced tumour typing and differential diagnosis	13,33
Artificial Intelligence	Machine learning, deep learning, digital pathology, foundation models	Improved diagnostic accuracy and workflow efficiency	14,28,30
Standardized Reporting	Structured pathology reporting and Living Evidence Gap Map	Greater international consistency and quality assurance	15,34

Genetic Tumour Syndromes	Expanded integration of hereditary gastrointestinal cancer syndromes	Early identification of inherited cancer predisposition	18,35
Neuroendocrine Neoplasms	Updated grading and classification with emphasis on tumour biology	Improved prognostic stratification and treatment planning	22,27
Precision Oncology	Histomolecular diagnosis and clinically actionable biomarkers	Personalized therapeutic decision-making	11,32
Public Health	Standardized classification supporting registries, surveillance, and research	Improved epidemiology and health policy planning	19,36

Table 3. Clinical Implications of the WHO 6th Edition in Gastrointestinal Oncology

Clinical Area	Contribution of WHO 6th Edition	Expected Benefit	Reference(s)
Pathological Diagnosis	Integrated histopathological, immunohistochemical, and molecular classification	Higher diagnostic accuracy	1,2
Prognostic Assessment	Recognition of biologically distinct tumour subtypes	Better risk stratification	12,13
Precision Medicine	Inclusion of predictive molecular biomarkers	Appropriate patient selection for targeted therapy and immunotherapy	10,11
Multidisciplinary Care	Standardized reporting across pathology and oncology teams	Improved clinical communication	15,39–42
Research	Uniform diagnostic criteria for multicentre studies	Improved comparability of research findings	19,36
Cancer Registries	Standardized tumour nomenclature	Reliable epidemiological surveillance	19,36
Education	Updated classification and digital resources	Enhanced pathology training	23,29
Future Innovation	Integration of AI, digital pathology, and molecular diagnostics	Continuous refinement of diagnostic practice	28–30

References

1. International Agency for Research on Cancer. **Cancer Today: GLOBOCAN 2022**. Lyon: International Agency for Research on Cancer; 2024.

2. World Health Organization Classification of Tumours Editorial Board. **WHO Classification of Tumours of the Digestive System**. 6th ed. Lyon: International Agency for Research on Cancer; 2025.

3. Arends MJ, Esposito I, Gill AJ, Hruban RH, Khoury JD, Kojima M, Montgomery EA, et al. Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. Histopathology. 2026;88(7):1295-1314. doi:10.1111/his.70116.

4. World Health Organization Classification of Tumours Editorial Board. **Digestive System Tumours**. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

5. Sukhera J. Narrative reviews: Flexible, rigorous, and practical. J Grad Med Educ. 2022;14(4):414-417.

6. National Comprehensive Cancer Network. **NCCN Clinical Practice Guidelines in Oncology: Colon Cancer**. Version 2025.

7. National Comprehensive Cancer Network. **NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer**. Version 2025.

8. National Comprehensive Cancer Network. **NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer**. Version 2025.

9. National Comprehensive Cancer Network. **NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers**. Version 2025.

10. European Society for Medical Oncology. **ESMO Clinical Practice Guideline for Gastric Cancer**. Ann Oncol. 2024.

11. European Society for Medical Oncology. **ESMO Clinical Practice Guideline for Colorectal Cancer**. Ann Oncol. 2024.

12. Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Gastroenterology. 2021;160(3):690-709.

13. Rosenbaum MW, Gonzalez RS. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Semin Diagn Pathol. 2022;39(1):48-57.

14. Wang X, Zhao J, Marostica E, Yuan J, Jin L, Wang P, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024;634:970-978.

15. Colling R, Indave BI, Del Aguila J, Cierco Jimenez R, Campbell F, Chechlińska M, et al. Moving forward on tumour pathology research reporting: A guide for pathologists from the World Health Organization Classification of Tumours Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 2024;37(7):100515.

16. Lawler M, Davies L, Oberst S, Valverde C, Burki TK, Remon J, et al. European Groundshot—Addressing Europe's cancer research challenges: A Lancet Oncology Commission. Lancet Oncol. 2023;24(1):e11-e56.

17. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.

18. Cree IA, Arends MJ, Khoury JD, Denton ERE, Gill AJ, Lazar AJ, et al. The WHO Classification of Genetic Tumour Syndromes: Considerations for histopathology. Histopathology. 2026;88(7):1291-1294.

19. Wijesinghe H, Puspanathan P, Giesen C, Indave Ruiz BI, Krpelanova E, Rous B, et al. Impact of WHO Classification of Tumours on cancer prevention, diagnosis, research, public health, and economics. J Natl Cancer Inst Monogr. 2026;(72):86-94.

20. Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. **WHO Classification of Tumours of the Digestive System**. 4th ed. Lyon: IARC; 2010.

21. Ortiz Requena D, Montgomery EA. What's new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026. Hum Pathol. 2026;169:106025.

22. Rindi G, Klimstra DS, et al. The evolution of the WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115-154.

23. Lokuhetty D, White VA, Watanabe R, et al., editors. **WHO Classification of Tumours Online**. Lyon: International Agency for Research on Cancer; 2025.

24. Washington MK, Goldberg RM, Chang GJ, Limburg PJ, Lam AK, Salto-Tellez M, et al. Diagnosis of digestive system

tumours. Int J Cancer. 2021;148(5):1040-1050. doi:10.1002/ijc.33210.
25. Loughrey MB, Wong NACS. Clinical utility of GI pathology data: Implications for practising pathologists. J Clin Pathol. 2022;75(8):519-524. doi:10.1136/jclinpath-2021-207472.
26. Ortiz Requena D, Montgomery EA. What's new in upper gastrointestinal pathology: Key updates and evolving challenges in 2026. Hum Pathol. 2026;169:106025. doi:10.1016/j.humpath.2025.106025.
27. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. The evolution of the WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115-154.
28. Kobayashi S, Saltz JH, Yang VW. State of machine and deep learning in histopathological applications in digestive diseases. World J Gastroenterol. 2021;27(20):2545-2575. doi:10.3748/wjg.v27.i20.2545.
29. Lokuhetty D, White VA, Watanabe R, et al., editors. WHO Classification of Tumours Online. Lyon: International Agency for Research on Cancer; 2025.
30. Wang X, Zhao J, Marostica E, Yuan J, Jin L, Wang P, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024;634:970-978.
31. Lawler M, Davies L, Oberst S, Valverde C, Burki TK, Remon J, et al. European Groundshot—Addressing Europe's cancer research challenges: A Lancet Oncology Commission. Lancet Oncol. 2023;24(1):e11-e56.
32. Grady WM, Yu M, Markowitz SD. Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer. Gastroenterology. 2021;160(3):690-709.
33. Rosenbaum MW, Gonzalez RS. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Semin Diagn Pathol. 2022;39(1):48-57.
34. Colling R, Indave BI, Del Aguila J, Cierco Jimenez R, Campbell F, Chechlińska M, et al. Moving forward on tumour pathology research reporting: A guide for pathologists from the WHO Classification of Tumours Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 2024;37(7):100515.
35. Cree IA, Arends MJ, Khoury JD, Denton ERE, Gill AJ, Lazar AJ, et al. The WHO Classification of Genetic Tumour Syndromes: Considerations for histopathology. Histopathology. 2026;88(7):1291-1294.
36. Wijesinghe H, Puspanathan P, Giesen C, Indave Ruiz BI, Krpelanova E, Rous B, et al. Impact of WHO Classification of Tumours on cancer prevention, diagnosis, research, public health, and economics. J Natl Cancer Inst Monogr. 2026;(72):86-94.
37. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
38. Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
39. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2025.
40. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2025.
41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2025.
42. European Society for Medical Oncology. ESMO Clinical Practice Guideline for Colorectal Cancer. Ann Oncol. 2024.
43. World Health Organization Classification of Tumours Editorial Board. WHO Classification of Tumours: Haematolymphoid Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2024.